Assel Kaliyeva
Family · Kissimmee, FLNPI 1891423166
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,148 and has fallen 61.4% since, to $829 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $36.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$456
- Amgen$336
- Novo Nordisk$304
- Bayer$282
- AstraZeneca$196
- Astellas Pharma US Inc$190
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,94697%
- Education$1193%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $456 |
| Amgen | 8 | $336 |
| Novo Nordisk | 7 | $304 |
| Bayer | 7 | $282 |
| AstraZeneca | 5 | $196 |
| Astellas Pharma US Inc | 2 | $190 |
| Kestra Medical Technology Services, Inc. | 2 | $185 |
| Corium, LLC | 3 | $179 |
| Boehringer Ingelheim | 5 | $177 |
| Lilly USA, LLC | 5 | $165 |
| GSK | 5 | $161 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $152 |
| Cvrx, Inc. | 1 | $140 |
| Procept Biorobotics Corporation | 1 | $137 |
| Otsuka America Pharmaceutical, Inc. | 2 | $132 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| Genentech USA, Inc. | 1 | $93 |
| Novartis | 4 | $82 |
| Exact Sciences | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Neurocrine Biosciences, Inc. | 3 | $63 |
| Boston Scientific | 2 | $61 |
| Mylan Specialty L.p. | 2 | $44 |
| Pfizer | 2 | $36 |
| Medtronic | 2 | $36 |
| Lundbeck LLC | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Cardiovascular Systems Inc. | 1 | $26 |
| Shield Therapeutics Inc | 1 | $19 |
| Biotronik Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$244
- Wegovy$237
- Assure WCD$161
- ADLARITY$147
- Barostim Neo System$140
- AQUABEAM SYSTEM$137
- Veozah$125
- VRAYLAR$125
- Kerendia$125
- FARXIGA$125
- LIBTAYO$121
- QULIPTA$108
- UBRELVY$108
- REXULTI$106
How this compares
$4,065 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $65,184 |
| OzempicSemaglutide | 19 | $19,087 |
| EntrestoSacubitril/Valsartan | 21 | $17,506 |
| MyrbetriqMirabegron | 19 | $8,251 |
| Memantine Hcl | 134 | $5,532 |
| Rosuvastatin Calcium | 87 | $1,933 |
| Levothyroxine Sodium | 148 | $1,639 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,252 |
| Donepezil Hcl | 87 | $1,170 |
| Diclofenac Sodium | 29 | $1,090 |
| Budesonide DrBudesonide | 11 | $1,086 |
| Metoprolol Succinate | 62 | $1,076 |
| Losartan Potassium | 94 | $963 |
| Solifenacin Succinate | 16 | $951 |
| Pantoprazole Sodium | 75 | $946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $65,18483 claims |
| Novo NordiskOzempic | $304 | $19,08719 claims |
| NovartisEntresto | $82 | $17,50621 claims |
| Astellas Pharma US IncMyrbetriq | $190 | $8,25119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Kissimmee
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.